Lonza, a supplier to the pharmaceutical, biotech and specialty ingredients markets, has entered into drug product services to offer customers a complete portfolio of development and manufacturing services for clinical outsourcing requirements.
This new service offering is part of Lonza’s drive to enable customers to meet some of the greatest challenges in patient treatment. These drug product services will focus on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other routes of parenteral administration. Services will include options for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules that require a parenteral dosage form.
Drug product services will be offered in the fourth quarter of 2016 from laboratories based in Basel (Switzerland), with an initial focus on formulation development and drug product analytical development and quality control. Specialised services will also be available for customers, such as particulate identification, characterisation and quantification, excipient and surfactant characterisation, extractables & leachables assessment and testing of container closure integrity. Drug product manufacturing capabilities for preclinical and clinical use (cGMP) will be available in late 2016.
“Expansion of our portfolio into drug product services fits well with our existing and future customers’ needs and is an important step in becoming a one-stop-shop for all clinical outsourcing requirements,” said Marc Funk, COO of Lonza.
This new service offering is part of Lonza’s drive to enable customers to meet some of the greatest challenges in patient treatment. These drug product services will focus on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other routes of parenteral administration. Services will include options for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules that require a parenteral dosage form.
Drug product services will be offered in the fourth quarter of 2016 from laboratories based in Basel (Switzerland), with an initial focus on formulation development and drug product analytical development and quality control. Specialised services will also be available for customers, such as particulate identification, characterisation and quantification, excipient and surfactant characterisation, extractables & leachables assessment and testing of container closure integrity. Drug product manufacturing capabilities for preclinical and clinical use (cGMP) will be available in late 2016.
“Expansion of our portfolio into drug product services fits well with our existing and future customers’ needs and is an important step in becoming a one-stop-shop for all clinical outsourcing requirements,” said Marc Funk, COO of Lonza.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%